Patents by Inventor Seonmi Kang

Seonmi Kang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapies with 3rd generation EGFR tyrosine kinase inhibitors
    Patent number: 11850248
    Abstract: The present invention relates to therapies with 3rd generation EGFR tyrosine kinase inhibitors. Embodiments of the invention relate to the administration of lazertinib to patients diagnosed with non-small cell lung cancer (NSCLC).
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: December 26, 2023
    Assignee: Yuhan Corporation
    Inventors: Seonmi Kang, Sewoong Oh
  • THERAPIES WITH 3RD GENERATION EGFR TYROSINE KINASE INHIBITORS
    Publication number: 20200360394
    Abstract: The present invention relates to therapies with 3rd generation EGFR tyrosine kinase inhibitors. Embodiments of the invention relate to the administration of lazertinib to patients diagnosed with non-small cell lung cancer (NSCLC).
    Type: Application
    Filed: May 14, 2020
    Publication date: November 19, 2020
    Inventors: Seonmi Kang, Sewoong Oh